D-Galactose

PreclinicalSmall molecule

CChildren's National Research Institute

D-Galactose is one of 27 small molecule programs targeting Nephrotic Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nephrotic SyndromeActive, not recruiting

Nephrotic SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Nephrotic Syndrome

#DrugCompanyPhaseTrials

Rituxan

Roche

Approved

15 2

Cellcept

Roche

Approved

7 3

Farxiga

AstraZeneca

Approved

3 4

Neoral

Novartis

Approved

2 5

Lovenox

Sanofi

Approved

1 6

Rayos

RRoxane Laboratories

Approved

4 7

Aldactone

Thalitone

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 10

Decadron

AAspen Global Incorporated

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nephrotic Syndrome1 trial

Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome

Completed·—·N/A·NCT01113385·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for D-Galactose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D-Galactose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D-Galactose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Children's National Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CChildren's National Research Institute

D-Galactose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nephrotic Syndrome1 trial

References

Drug Info

Quick Facts

Related News